Skip to content

US · ACXP · BIOTECHNOLOGY

Acurx Pharmaceuticals, Inc. (ACXP) intrinsic value and stock valuation

$1.04as of 2026-11-21 · Mkt cap 2.33M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Acurx Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ACXP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACXP’s statements →

Acurx Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Staten Island, NY 10305 acurxpharma.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-7.97M
20192025
Free cash flow
-$-6.79B
20192025
Total equity
$5.27M+14.3% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-8.09M-$-14.1M-$-14.58M-$-12.09M-$-12.81M
Net income-$-7.97M-$-14.1M-$-14.58M-$-12.09M-$-12.75M
EPSd-$-5.31M-$-16.59M-$-23.14M-$-22.39M-$-25M
Operating cash flow-$-6.79B-$-10.38M-$-9.8M-$-7.54M-$-5.01M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-6.79B-$-10.38M-$-9.8M-$-7.54M-$-5.01M
Total assets$7.69M$3.86M$7.71M$9.38M$13.3M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.56B-$-3.71M-$-7.47M-$-9.11M-$-12.96M
Total equity$5.27M$620K$4.67M$7.32M$12.4M
Cash and short-term investments$7.56B$3.71M$7.47M$9.11M$13M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$1.83B$5.4M$6.04M$4.75M$2.03M
Selling, general and administrative expenses$6.26B$8.7M$8.53M$7.34M$10.8M
Other expenses-$-8.08B$0.00$0.00$0.00$0.00
Operating expenses$8.09M$14.1M$14.6M$12.1M$12.8M
Cost and expenses$8.09M$14.1M$14.6M$12.1M$12.8M
Interest income$130K$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$14.1M$0.00$0.00$0.00
Ebitda-$-7.97M$0.00-$-14.58M-$-12.09M-$-12.75M
Operating income-$-8.09M-$-14.1M-$-14.58M-$-12.09M-$-12.81M
Total other income/expenses, net$130K$0.00$0.00$0.00$70K
Income before tax-$-7.97M-$-14.1M-$-14.58M-$-12.09M-$-12.75M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.97M-$-14.1M-$-14.58M-$-12.09M-$-12.75M
Weighted average shares outstanding$1.5M$850K$630K$540K$510K
Weighted average diluted shares outstanding$1.5M$850K$630K$540K$510K
Balance sheet
20252024202320222021
Cash and short-term investments$7.56B$3.71M$7.47M$9.11M$13M
Net receivables$50K$50K$130K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$7.69M$3.86M$7.71M$9.38M$13.3M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$0.00$0.00
Total assets$7.69M$3.86M$7.71M$9.38M$13.3M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.42M$3.24M$3.04M$2.06M$840K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$2.42M$3.24M$3.04M$2.06M$840K
Common stock$0.00$20K$10K$10K$10K
Retained earnings-$-75.29M-$-67.32M-$-53.22M-$-38.64M-$-26.55M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-38.64M-$-26.55M
Total equity$5.27M$620K$4.67M$7.32M$12.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.56B-$-3.71M-$-7.47M-$-9.11M-$-12.96M
Cash flow statement
20252024202320222021
Net income-$-7.97B-$-14.1M-$-14.58M-$-12.09M-$-12.75M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$1.25B$3.44M$3.77M$3.3M$6.74M
Change in working capital-$-390K$280K$1.01M$1.25M$140K
Accounts receivable$0.00$80K-$-130K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-6.79B-$-10.38M-$-9.8M-$-7.54M-$-5.01M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$10.6M$6.41M$5.94M$3.7M$14.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.6B$6.62M$8.16M$3.7M$14.8M
Net change in cash$3.85B-$-3.77M-$-1.64M-$-3.85M$9.78M
Cash at end of period$7.56B$3.71M$7.47M$9.11M$13M
Operating cash flow-$-6.79B-$-10.38M-$-9.8M-$-7.54M-$-5.01M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-6.79B-$-10.38M-$-9.8M-$-7.54M-$-5.01M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Acurx Pharmaceuticals, Inc.

        Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

        CEO
        David Luci
        Employees
        4
        Beta
        -2.04

        Explore

        Frequently asked questions

        What is the intrinsic value of Acurx Pharmaceuticals, Inc. (ACXP)?

        InvestorsCraft does not currently publish an intrinsic value for ACXP. How the IC value is calculated.

        Is ACXP undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACXP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.